Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 3
1966 3
1968 1
1969 1
1970 2
1971 1
1972 4
1973 2
1974 7
1975 6
1976 4
1977 9
1978 10
1979 19
1980 16
1981 19
1982 15
1983 12
1984 15
1985 6
1986 14
1987 31
1988 41
1989 61
1990 58
1991 70
1992 98
1993 94
1994 103
1995 126
1996 119
1997 120
1998 109
1999 127
2000 136
2001 147
2002 158
2003 137
2004 184
2005 160
2006 185
2007 184
2008 169
2009 197
2010 181
2011 201
2012 218
2013 205
2014 247
2015 245
2016 275
2017 239
2018 218
2019 220
2020 234
2021 260
2022 276
2023 221
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5,788 results

Results by year

Filters applied: . Clear all
Page 1
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, Varricchio S, Casadio P, Inzani F, Seracchioli R, Mollo A, Mascolo M, Zannoni GF. Arciuolo D, et al. Int J Mol Sci. 2022 Oct 2;23(19):11684. doi: 10.3390/ijms231911684. Int J Mol Sci. 2022. PMID: 36232987 Free PMC article. Review.
The four TCGA-based molecular prognostic groups of endometrial carcinoma (EC), i.e., POLE-mutant, mismatch repair (MMR)-deficient, p53-abnormal, and "no specific molecular profile" (NSMP), have recently been integrated into ESGO-ESTRO-ESP guidelines. ...
The four TCGA-based molecular prognostic groups of endometrial carcinoma (EC), i.e., POLE-mutant, mismatch repair (MMR)-defici …
Endometrial cancer in Lynch syndrome.
Zhao S, Chen L, Zang Y, Liu W, Liu S, Teng F, Xue F, Wang Y. Zhao S, et al. Int J Cancer. 2022 Jan 1;150(1):7-17. doi: 10.1002/ijc.33763. Epub 2021 Sep 9. Int J Cancer. 2022. PMID: 34398969 Free article. Review.
Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline pathogenic variants (PVs) in mismatch repair (MMR) genes. LS-associated endometrial cancer (LS-EC) is the most common extraintestinal sentinel cancer caused by germline PVs in MMR genes, incl …
Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline pathogenic variants (PVs) in mismatch repair (MMR) genes. …
Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.
Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG, Gilks CB. Soslow RA, et al. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S64-S74. doi: 10.1097/PGP.0000000000000518. Int J Gynecol Pathol. 2019. PMID: 30550484 Free PMC article. Review.
In this review, we sought to address 2 important issues in the diagnosis of endometrial carcinoma: how to grade endometrial endometrioid carcinomas and how to incorporate the 4 genomic subcategories of endometrial carcinoma, as identified throug …
In this review, we sought to address 2 important issues in the diagnosis of endometrial carcinoma: how to grade endometrial …
Molecular Genetics of Endometrial Carcinoma.
Bell DW, Ellenson LH. Bell DW, et al. Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17. Annu Rev Pathol. 2019. PMID: 30332563 Review.
Endometrioid endometrial carcinomas constitute approximately 85% of newly diagnosed cases; serous carcinomas represent approximately 3-10% of diagnoses; clear cell carcinoma accounts for <5% of diagnoses; and uterine carcinosarcomas are rare, biphasic tumors. ... …
Endometrioid endometrial carcinomas constitute approximately 85% of newly diagnosed cases; serous carcinomas represent approximately …
Incorporation of molecular characteristics into endometrial cancer management.
Vermij L, Smit V, Nout R, Bosse T. Vermij L, et al. Histopathology. 2020 Jan;76(1):52-63. doi: 10.1111/his.14015. Histopathology. 2020. PMID: 31846532 Free PMC article. Review.
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. This provides clinicians with prognostic information and input for further treatment recommendations. Nonetheless, patients with histological …
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. T …
Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis.
Huvila J, Pors J, Thompson EF, Gilks CB. Huvila J, et al. J Pathol. 2021 Apr;253(4):355-365. doi: 10.1002/path.5608. Epub 2021 Feb 6. J Pathol. 2021. PMID: 33368243 Review.
Endometrial carcinoma (EC) is classified into a wide range of morphological variants; this list has expanded over the past decade with the inclusion of mesonephric-like and dedifferentiated carcinoma as EC variants in the fifth edition of the WHO Classificati …
Endometrial carcinoma (EC) is classified into a wide range of morphological variants; this list has expanded over the past dec …
Endometrial cancer.
Sorosky JI. Sorosky JI. Obstet Gynecol. 2012 Aug;120(2 Pt 1):383-97. doi: 10.1097/AOG.0b013e3182605bf1. Obstet Gynecol. 2012. PMID: 22825101 Review.
The epidemiology, prevention, diagnosis, treatment, prognosis, and new International Federation of Gynecology and Obstetrics staging system of endometrial carcinoma are reviewed. Endometrial cancer has increased 21% in incidence since 2008, and the death rate …
The epidemiology, prevention, diagnosis, treatment, prognosis, and new International Federation of Gynecology and Obstetrics staging system …
Clear cell carcinoma of the endometrium.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher D, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM Jr, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, Bini M, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Gynecol Oncol. 2022 Mar;164(3):658-666. doi: 10.1016/j.ygyno.2022.01.012. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063279 Review.
Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. ...Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial …
Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. ...Moreover, ongoing clinical trials tes …
Facts and Hopes in Immunotherapy of Endometrial Cancer.
Marín-Jiménez JA, García-Mulero S, Matías-Guiu X, Piulats JM. Marín-Jiménez JA, et al. Clin Cancer Res. 2022 Nov 14;28(22):4849-4860. doi: 10.1158/1078-0432.CCR-21-1564. Clin Cancer Res. 2022. PMID: 35789264 Review.
Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many tumors, and endometrial carcinoma is not an exception. Approved treatment options are pembrolizumab or dostarlimab for mismatch repair deficient tumors, pembrolizumab for tumors …
Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many tumors, and endometrial carcinoma is n …
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, González-Martín A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X. Concin N, et al. Virchows Arch. 2021 Feb;478(2):153-190. doi: 10.1007/s00428-020-03007-z. Virchows Arch. 2021. PMID: 33604759 Free article.
A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, …
A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelin …
5,788 results